Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-07-31 DOI:10.1016/j.jtocrr.2024.100712

Shetal A. Patel MD, PhD , Young Whang MD, PhD , Chaely Medley NP , Kevin Chen PharmD , Jasmine Jordan BS , Dante Bortone PhD , Benjamin Vincent MD, PhD , Jared Weiss MD

引用次数: 0

Abstract

A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.

查看原文本刊更多论文

塔拉他单抗治疗一名年轻成人的大细胞神经内分泌癌：病例报告

一名患有转移性肺大细胞神经内分泌癌的 20 岁男子接受了 delta-like ligand 3 靶向双特异性 T 细胞捕获剂 tarlatamab 的治疗。治疗过程中出现了一过性细胞因子释放综合征，但最终取得了部分疗效。双特异性T细胞捕获剂可能会为肺大细胞神经内分泌癌提供一种新的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊